HomeAI · summaries
Storia in 3 fonti
AstraZeneca tozorakimab COPD Phase 3 trial results 2026
The drug reduced flare-ups in a broader patient population than existing COPD biologics, with U.S. approval expected in early 2027
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
abcnews.com
New drug shows promise in reducing COPD symptoms in former and current smokers, clinical trials show
A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to the CDC.
- ·
cnbc.com
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
